Literature DB >> 11004147

Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II.

J P van Kats1, D J Duncker, D B Haitsma, M P Schuijt, R Niebuur, R Stubenitsky, F Boomsma, M A Schalekamp, P D Verdouw, A H Danser.   

Abstract

BACKGROUND: The mechanisms behind the beneficial effects of renin-angiotensin system blockade after myocardial infarction (MI) are not fully elucidated but may include interference with tissue angiotensin II (Ang II). METHODS AND
RESULTS: Forty-nine pigs underwent coronary artery ligation or sham operation and were studied up to 6 weeks. To determine coronary angiotensin I (Ang I) to Ang II conversion and to distinguish plasma-derived Ang II from locally synthesized Ang II, (125)I-labeled and endogenous Ang I and II were measured in plasma and in infarcted and noninfarcted left ventricle (LV) during (125)I-Ang I infusion. Ang II type 1 (AT(1)) receptor-mediated uptake of circulating (125)I-Ang II was increased at 1 and 3 weeks in noninfarcted LV, and this uptake was the main cause of the transient elevation in Ang II levels in the noninfarcted LV at 1 week. Ang II levels and AT(1) receptor-mediated uptake of circulating Ang II were reduced in the infarct area at all time points. Coronary Ang I to Ang II conversion was unaffected by MI. Captopril and the AT(1) receptor antagonist eprosartan attenuated postinfarct remodeling, although both drugs increased cardiac Ang II production. Captopril blocked coronary conversion by >80% and normalized Ang II uptake in the noninfarcted LV. Eprosartan did not affect coronary conversion and blocked cardiac Ang II uptake by >90%.
CONCLUSIONS: Both circulating and locally generated Ang II contribute to remodeling after MI. The rise in tissue Ang II production during angiotensin-converting enzyme inhibition and AT(1) receptor blockade suggests that the antihypertrophic effects of these drugs result not only from diminished AT(1) receptor stimulation but also from increased stimulation of growth-inhibitory Ang II type 2 receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004147     DOI: 10.1161/01.cir.102.13.1556

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

Authors:  Martin P Schuijt; René de Vries; Pramod R Saxena; Maarten A D H Schalekamp; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction.

Authors:  Birgit Houweling; Daphne Merkus; Oana Sorop; Frans Boomsma; Dirk J Duncker
Journal:  J Physiol       Date:  2006-05-18       Impact factor: 5.182

Review 3.  'Integrative Physiology 2.0': integration of systems biology into physiology and its application to cardiovascular homeostasis.

Authors:  Diederik W D Kuster; Daphne Merkus; Jolanda van der Velden; Adrie J M Verhoeven; Dirk J Duncker
Journal:  J Physiol       Date:  2011-01-04       Impact factor: 5.182

4.  Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Authors:  Jan Wysocki; Minghao Ye; Ahmed M Khattab; Agnes Fogo; Aline Martin; Nicolae Valentin David; Yashpal Kanwar; Mark Osborn; Daniel Batlle
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

Review 5.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 6.  Is angiotensin II made inside or outside of the cell?

Authors:  Wenxia Chai; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 7.  Myofilament dysfunction in cardiac disease from mice to men.

Authors:  Nazha Hamdani; Monique de Waard; Andrew E Messer; Nicky M Boontje; Viola Kooij; Sabine van Dijk; Amanda Versteilen; Regis Lamberts; Daphne Merkus; Cris Dos Remedios; Dirk J Duncker; Attila Borbely; Zoltan Papp; Walter Paulus; Ger J M Stienen; Steven B Marston; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2009-01-13       Impact factor: 2.698

8.  Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.

Authors:  Joep H M van Esch; Florian Gembardt; Anja Sterner-Kock; Silvia Heringer-Walther; Thu H Le; Dirk Lassner; Theo Stijnen; Thomas M Coffman; Heinz-Peter Schultheiss; A H Jan Danser; Thomas Walther
Journal:  Cardiovasc Res       Date:  2010-01-12       Impact factor: 10.787

9.  A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.

Authors:  Ali Ahmed; Bertram Pitt
Journal:  Am J Cardiol       Date:  2009-04-01       Impact factor: 2.778

10.  Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway.

Authors:  Jian Yang; Hong Jiang; Jun Yang; Jia-Wang Ding; Li-Hua Chen; Song Li; Xiao-Dong Zhang
Journal:  Mol Cell Biochem       Date:  2009-04-16       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.